Shortly after winning a stay on a COVID-19 vaccine patent lawsuit brought by Moderna, Pfizer and its German partner BioNTech are being dragged into another round of mRNA litigation by GSK.
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
LONDON, April 23 (Reuters) - Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday.
MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, BioNTech or the Company) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024....
After nearly two years of legal back and forth, Pfizer and its German partner BioNTech have won a brief reprieve in their patent fight against mRNA rival Moderna.
Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell...
BioNTech gets US agency notice over default on COVID vaccine royalties
Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) “ BioNTech SE (Nasdaq: BNTX, BioNTech or the Company) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management...
Advanced oncology pipeline in mid- and late-stage with plans to have ten or more potentially registrational oncology trials running by the end of 2024Aiming for first oncology launch in 2026 and...
BioNTech has hired one of Novartis’ radioligand therapy leaders as its new chief commercial officer, as the company looks to pivot from reliance on its Covid franchise and become a multi-product company.